Cargando…
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
Autores principales: | Groen, Kazimierz, Schjesvold, Fredrik H., van der Holt, Bronno, Levin, Mark-David, Seefat, Maarten R., Hansson, Markus, Leys, Maria B.L., Regelink, Josien C., Waage, Anders, Szatkowski, Damian, Axelsson, Per, Hieu Do, Trung, Svirskaite, Asta, van der Spek, Ellen, Haukas, Einar, Knut-Bojanowska, Dorota, Ypma, Paula F., Blimark, Cecilie H., Mellqvist, Ulf-Henrik, van de Donk, Niels W.C.J., Sonneveld, Pieter, Klostergaard, Anja, Vangsted, Annette J., Abildgaard, Niels, Zweegman, Sonja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470677/ https://www.ncbi.nlm.nih.gov/pubmed/37663673 http://dx.doi.org/10.1097/HS9.0000000000000940 |
Ejemplares similares
-
P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13
por: Groen, K., et al.
Publicado: (2022) -
Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
por: Zweegman, Sonja, et al.
Publicado: (2020) -
P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
por: Groen, Kaz, et al.
Publicado: (2023) -
P906: IXAZOMIB, DARATUMUMAB AND LOW DOSE DEXAMETHASONE IN FRAIL PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS OF THE MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
por: Groen, K., et al.
Publicado: (2022) -
P13 IXAZOMIB, DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
por: Groen, K., et al.
Publicado: (2023)